Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Cash Flow for Dividends: €-199 Mil (TTM As of Mar. 2026)


FRA:GU5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
71 GF Score
Price €1.55
GF Value €2.30
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Cash Flow for Dividends?

Guangzhou Baiyunshan Pharmaceutical Holdings Co FRA:GU5 -1.27% 71 Cash Flow for Dividends is €-199 Mil as of Mar. 2026. GuruFocus rates FRA:GU5 with a GF Score™ of 71/100 and a GF Value™ of €2.30 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's cash flow for dividends for the three months ended in Mar. 2026 was €-11 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €-199 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's quarterly payment of dividends declined from Sep. 2025 (€-98 Mil) to Dec. 2025 (€-11 Mil) but then increased from Dec. 2025 (€-11 Mil) to Mar. 2026 (€-11 Mil).

Guangzhou Baiyunshan Pharmaceutical Holdings Co's annual payment of dividends increased from Dec. 2023 (€-204 Mil) to Dec. 2024 (€-295 Mil) but then declined from Dec. 2024 (€-295 Mil) to Dec. 2025 (€-200 Mil).

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cash Flow for Dividends Related Terms

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cash Flow for Dividends Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -175.92 -201.83 -203.58 -295.22 -199.77

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.72 -79.19 -97.58 -11.13 -11.34
FRA:GU5
71GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-199 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €-199 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Cash Flow for Dividends of €-199 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cash Flow for Dividends too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Cash Flow for Dividends is €-199 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cash Flow for Dividends compare to MCK and CAH?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cash Flow for Dividends of €-199 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Distribution company?
A good Cash Flow for Dividends depends on the Medical Distribution industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Cash Flow for Dividends is €-199 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.55 — trading 32.6% below its estimated fair value. The current Cash Flow for Dividends is €-199 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Cash Flow for Dividends is €-199 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of €1.55 is trading 32.6% below its estimated GF Value™ of €2.30. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for FRA:GU5:

  • Cash Flow for Dividends: €-199 Mil
  • GF Value™: €2.30 vs. price of €1.55 (32.6% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges 00874:Hong Kong600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
71GF Score

Get the complete analysis for FRA:GU5

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€2.30
GF Value